[Immunoglobulins and physiopathology: actual indications].
Intravenous Immunoglobulin (IVIg) are therapeutic preparations of normal human IgG that are obtained from pools of plasma from healthy blood donors. IVIg can be used at high dose as an immunomodulatory agent in a large number of autoimmune and/or systemic inflammatory diseases, particularly in hematologic or neurologic diseases. Mechanisms of action of IVIg are multiple and intricate. The development of new therapeutic trials in association with analyses of mechanisms of action should help to define new indications of IVIg therapy.
Mouthon
L
L
Hôpital Cochin, Paris, France. luc.mouthon@cch.aphp.fr
Guilpain
P
P
D001323:Autoantibodies / Q000187:drug effects; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology*; D020274:Autoimmune Diseases of the Nervous System / Q000188:drug therapy / Q000503:physiopathology; D018925:Chemokines; D003165:Complement System Proteins / Q000187:drug effects; D016207:Cytokines / Q000187:drug effects; D003712:Dendrites / Q000187:drug effects; D005602:France; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000494:pharmacology* / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000494:pharmacology* / Q000627:therapeutic use*; D008214:Lymphocytes / Q000187:drug effects; D009000:Monocytes / Q000187:drug effects; D009157:Myasthenia Gravis / Q000188:drug therapy / Q000503:physiopathology; D011129:Polyradiculoneuropathy / Q000188:drug therapy / Q000503:physiopathology; D017410:Practice Guidelines as Topic
D001323:Autoantibodies; D018925:Chemokines; D016207:Cytokines; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D003165:Complement System Proteins